Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 15/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.63 |
| ▸ | PRKDC | P78527 | 1/20 | 0.63 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188893 | 0.94 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188775 | 0.94 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL221252 | 0.93 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188267 | 0.92 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL6995964 | 0.92 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189876 | 0.91 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188889 | 0.88 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189404 | 0.87 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL187815 | 0.86 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL14053338 | 0.86 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012006552-A1 | COMBINATIONS OF KINASE INHIBITORS FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2364974-A1 | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors | Exelixis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |